{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T17:58:52Z","timestamp":1776362332728,"version":"3.51.2"},"reference-count":30,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2022,1,17]],"date-time":"2022-01-17T00:00:00Z","timestamp":1642377600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"EFRE-Staf","award":["85000915"],"award-info":[{"award-number":["85000915"]}]},{"DOI":"10.13039\/501100002347","name":"BMBF","doi-asserted-by":"publisher","award":["013L0132A"],"award-info":[{"award-number":["013L0132A"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Toxins"],"abstract":"<jats:p>Botulinum neurotoxin (BoNT) is used for the treatment of a number of ailments. The activity of the toxin that is isolated from bacterial cultures is frequently tested in the mouse lethality assay. Apart from the ethical concerns inherent to this assay, species-specific differences in the affinity for different BoNT serotypes give rise to activity results that differ from the activity in humans. Thus, BoNT\/B is more active in mice than in humans. The current study shows that the stimulus-dependent release of a luciferase from a differentiated human neuroblastoma\u2013based reporter cell line (SIMA-hPOMC1-26-Gluc) was inhibited by clostridial and recombinant BoNT\/A to the same extent, whereas both clostridial and recombinant BoNT\/B inhibited the release to a lesser extent and only at much higher concentrations, reflecting the low activity of BoNT\/B in humans. By contrast, the genetically modified BoNT\/B-MY, which has increased affinity for human synaptotagmin, and the BoNT\/B protein receptor inhibited luciferase release effectively and with an EC50 comparable to recombinant BoNT\/A. This was due to an enhanced uptake into the reporter cells of BoNT\/B-MY in comparison to the recombinant wild-type toxin. Thus, the SIMA-hPOMC1-26-Gluc cell assay is a versatile tool to determine the activity of different BoNT serotypes providing human-relevant dose-response data.<\/jats:p>","DOI":"10.3390\/toxins14010065","type":"journal-article","created":{"date-parts":[[2022,1,17]],"date-time":"2022-01-17T20:49:21Z","timestamp":1642452561000},"page":"65","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Discrimination of the Activity of Low-Affinity Wild-Type and High-Affinity Mutant Recombinant BoNT\/B by a SIMA Cell-Based Reporter Release Assay"],"prefix":"10.3390","volume":"14","author":[{"given":"Frank","family":"Neusch\u00e4fer-Rube","sequence":"first","affiliation":[{"name":"Department of Nutritional Biochemistry, Institute of Nutritional Science, University of Potsdam, 14469 Potsdam, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Pathe-Neusch\u00e4fer-Rube","sequence":"additional","affiliation":[{"name":"Department of Nutritional Biochemistry, Institute of Nutritional Science, University of Potsdam, 14469 Potsdam, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerhard P.","family":"P\u00fcschel","sequence":"additional","affiliation":[{"name":"Department of Nutritional Biochemistry, Institute of Nutritional Science, University of Potsdam, 14469 Potsdam, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,1,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1146\/annurev-biochem-013118-111654","article-title":"Botulinum and Tetanus Neurotoxins","volume":"88","author":"Dong","year":"2019","journal-title":"Annu. Rev. Biochem."},{"key":"ref_2","first-page":"1","article-title":"Genetic diversity within Clostridium botulinum serotypes, botulinum neurotoxin gene clusters and toxin subtypes","volume":"364","author":"Hill","year":"2013","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e00375-17","DOI":"10.1128\/genomeA.00375-17","article-title":"Finished Whole-Genome Sequences of Clostridium butyricum Toxin Subtype E4 and Clostridium baratii Toxin Subtype F7 Strains","volume":"5","author":"Halpin","year":"2017","journal-title":"Genome Announc."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Peck, M.W., Smith, T.J., Anniballi, F., Austin, J.W., Bano, L., Bradshaw, M., Cuervo, P., Cheng, L.W., Derman, Y., and Dorner, B.G. (2017). Historical Perspectives and Guidelines for Botulinum Neurotoxin Subtype Nomenclature. Toxins, 9.","DOI":"10.3390\/toxins9010038"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1093\/infdis\/jit450","article-title":"Molecular characterization of a novel botulinum neurotoxin type H gene","volume":"209","author":"Dover","year":"2014","journal-title":"J. Infect. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1111\/j.1471-4159.2009.06093.x","article-title":"Cell entry strategy of clostridial neurotoxins","volume":"109","author":"Binz","year":"2009","journal-title":"J. Neurochem."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"913","DOI":"10.3390\/toxins4100913","article-title":"Clinical uses of botulinum neurotoxins: Current indications, limitations and future developments","volume":"4","author":"Chen","year":"2012","journal-title":"Toxins"},{"key":"ref_8","first-page":"e7916","article-title":"A 10-year Retrospective Review of Botulinum Toxin Injections and Surgical Management of Sialorrhea","volume":"12","author":"Weitzman","year":"2020","journal-title":"Cureus"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/j.jaad.2019.11.042","article-title":"Botulinum toxin: Pharmacology and injectable administration for the treatment of primary hyperhidrosis","volume":"82","author":"Nawrocki","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/j.1533-2500.2008.00202.x","article-title":"Evidence for the use of botulinum toxin in the chronic pain setting\u2014A review of the literature","volume":"8","author":"Jeynes","year":"2008","journal-title":"Pain Pract."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1111\/jocd.13702","article-title":"The mechanisms of action and use of botulinum neurotoxin type A in aesthetics: Key Clinical Postulates II","volume":"19","author":"Nestor","year":"2020","journal-title":"J. Cosmet. Dermatol."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Spiegel, L.L., Ostrem, J.L., and Bledsoe, I.O. (2020). FDA Approvals and Consensus Guidelines for Botulinum Toxins in the Treatment of Dystonia. Toxins, 12.","DOI":"10.3390\/toxins12050332"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.tox.2008.04.018","article-title":"Effects of purification on the bioavailability of botulinum neurotoxin type A","volume":"249","author":"Cheng","year":"2008","journal-title":"Toxicology"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Pellett, S., Tepp, W.H., and Johnson, E.A. (2019). Critical analysis of neuronal cell and the mouse bioassay for detection of botulinum neurotoxins. Toxins, 11.","DOI":"10.3390\/toxins11120713"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.vascn.2017.04.013","article-title":"Assessment of ELISA as endpoint in neuronal cell-based assay for BoNT detection using hiPSC derived neurons","volume":"88","author":"Pellett","year":"2017","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Fern\u00e1ndez-Salas, E., Wang, J., Molina, Y., Nelson, J.B., Jacky, B.P.S., and Aoki, K.R. (2012). Botulinum neurotoxin serotype A specific cell-based potency assay to replace the mouse bioassay. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0049516"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Hobbs, R.J., Thomas, C.A., Halliwell, J., and Gwenin, C.D. (2019). Rapid detection of botulinum neurotoxins\u2014A review. Toxins, 11.","DOI":"10.3390\/toxins11070418"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.toxicon.2015.08.001","article-title":"Clinical differences between botulinum neurotoxin type A and B","volume":"107","author":"Bentivoglio","year":"2015","journal-title":"Toxicon"},{"key":"ref_19","first-page":"3233","article-title":"Botulinum neurotoxin D-C uses synaptotagmin I and II as receptors, and human synaptotagmin II is not an effective receptor for type B, D-C and G toxins","volume":"125","author":"Peng","year":"2012","journal-title":"J. Cell Sci."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.febslet.2011.12.037","article-title":"Human synaptotagmin-II is not a high affinity receptor for botulinum neurotoxin B and G: Increased therapeutic dosage and immunogenicity","volume":"586","author":"Strotmeier","year":"2012","journal-title":"FEBS Lett."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/0014-5793(95)01471-3","article-title":"The high-affinity binding of Clostridium botulinum type B neurotoxin to synaptotagmin II associated with gangliosides GT1b\/GD1a","volume":"378","author":"Nishiki","year":"1996","journal-title":"FEBS Lett."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41467-017-00064-y","article-title":"Engineered botulinum neurotoxin B with improved efficacy for targeting human receptors","volume":"8","author":"Tao","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Pathe-Neusch\u00e4fer-Rube, A., Neusch\u00e4fer-Rube, F., Haas, G., Langoth-Fehringer, N., and P\u00fcschel, G.P. (2018). Cell-Based reporter release assay to determine the potency of proteolytic bacterial neurotoxins. Toxins, 10.","DOI":"10.3390\/toxins10090360"},{"key":"ref_24","first-page":"297","article-title":"Botulinum neurotoxin dose-dependently inhibits release of neurosecretory vesicle-targeted luciferase from neuronal cells","volume":"32","author":"Genz","year":"2015","journal-title":"ALTEX"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Yin, L., Masuyer, G., Zhang, S., Zhang, J., Miyashita, S.-I., Burgin, D., Lovelock, L., Coker, S.-F., Fu, T.-M., and Stenmark, P. (2020). Characterization of a membrane binding loop leads to engineering botulinum neurotoxin B with improved therapeutic efficacy. PLoS Biol., 18.","DOI":"10.1371\/journal.pbio.3000618"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"eaau7196","DOI":"10.1126\/sciadv.aau7196","article-title":"Engineered botulinum neurotoxin B with improved binding to human receptors has enhanced efficacy in preclinical models","volume":"5","author":"Elliott","year":"2019","journal-title":"Sci. Adv."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.biologicals.2020.06.007","article-title":"Transferability study of the BINACLE (binding and cleavage) assay for in vitro determination of botulinum neurotoxin activity","volume":"67","author":"Bonifas","year":"2020","journal-title":"Biologicals"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Thaker, H., Zhang, J., Miyashita, S.-I., Cristofaro, V., Park, S., Hashemi Gheinani, A., Sullivan, M.P., Adam, R.M., and Dong, M. (2021). Knockin mouse models demonstrate differential contributions of synaptotagmin-1 and -2 as receptors for botulinum neurotoxins. PLoS Pathog., 17.","DOI":"10.1371\/journal.ppat.1009994"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Schenke, M., Schjeide, B.-M., P\u00fcschel, G.P., and Seeger, B. (2020). Analysis of motor neurons differentiated from human induced pluripotent stem cells for the use in cell-based botulinum neurotoxin activity Assays. Toxins, 12.","DOI":"10.3390\/toxins12050276"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Cotter, L., Yu, F., de Lamotte, J.D., Dong, M., Krupp, J., and Nicoleau, C. (2021). Split Luciferase-Based Assay to Detect Botulinum Neurotoxins Using Human Motor Neurons Derived From Induced Pluripotent Stem Cell, Research Square.","DOI":"10.21203\/rs.3.rs-730824\/v1"}],"container-title":["Toxins"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6651\/14\/1\/65\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:02:40Z","timestamp":1760133760000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6651\/14\/1\/65"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,17]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,1]]}},"alternative-id":["toxins14010065"],"URL":"https:\/\/doi.org\/10.3390\/toxins14010065","relation":{},"ISSN":["2072-6651"],"issn-type":[{"value":"2072-6651","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,17]]}}}